Summary
Bristol-Myers Squibb Company (BMY) reported its second-quarter 2014 financial results, demonstrating a significant strategic shift with the divestiture of its diabetes business to AstraZeneca in February 2014. This transaction contributed to a decrease in total revenues for both the three and six months ended June 30, 2014, compared to the prior year. While net earnings also declined on a GAAP basis, the company's Non-GAAP earnings per share showed an increase, highlighting the impact of significant "specified items" such as restructuring charges and IPRD impairments. The company continues to focus on its core therapeutic areas, particularly oncology and immunology, with significant pipeline developments, notably the advancement of Opdivo (nivolumab) in melanoma and lung cancer. The Eliquis (apixaban) franchise continues its strong growth trajectory. Despite revenue challenges in certain legacy products and geographic regions, BMY's strategic transformation appears to be driving improved operational performance on a non-GAAP basis and positioning the company for future growth through its robust R&D pipeline.
Financial Highlights
56 data points| Revenue | $3.89B |
| Cost of Revenue | $991.00M |
| Gross Profit | $2.90B |
| R&D Expenses | $1.42B |
| SG&A Expenses | $951.00M |
| Operating Expenses | $3.44B |
| Interest Expense | $46.00M |
| Net Income | $333.00M |
| EPS (Basic) | $0.20 |
| EPS (Diluted) | $0.20 |
| Shares Outstanding (Basic) | 1.66B |
| Shares Outstanding (Diluted) | 1.67B |
Key Highlights
- 1Total Revenues decreased by 4% to $3.9 billion for the three months ended June 30, 2014, and by 2% to $7.7 billion for the six months ended June 30, 2014, largely due to the divestiture of the diabetes business.
- 2Net Earnings Attributable to BMS decreased to $333 million ($0.20 per share) for the three months ended June 30, 2014, from $536 million ($0.32 per share) in the prior year, reflecting the impact of the diabetes business sale and other charges.
- 3Non-GAAP Diluted Earnings Per Share increased to $0.48 for the three months ended June 30, 2014, and to $0.94 for the six months ended June 30, 2014, indicating underlying operational improvements excluding special items.
- 4Research and development expenses significantly increased by 49% in the three-month period and 26% in the six-month period, driven by substantial IPRD impairment charges and the acquisition of iPierian.
- 5The company achieved significant progress with its immuno-oncology pipeline, particularly with Opdivo (nivolumab), which received accelerated assessment in the EU for melanoma and advanced regulatory submissions in the U.S. for melanoma and lung cancer.
- 6Sales of key growth products like Sprycel, Yervoy, Orencia, and Eliquis demonstrated strong double-digit percentage increases, partially offsetting declines in other areas.
- 7Cash, cash equivalents, and marketable securities increased to $11.1 billion as of June 30, 2014, significantly boosted by proceeds from the diabetes business divestiture.